Clinical Report: Ongoing Impact of Inflammatory Bowel Disease Despite Modern Treatments
Overview
A survey of IBD patients in Greece reveals significant disease burden despite advanced therapies. Key findings include high rates of impaired quality of life, work productivity loss, and treatment dissatisfaction.
Background
Inflammatory bowel disease (IBD), encompassing Crohn's disease (CD) and ulcerative colitis (UC), is a chronic condition that significantly impacts patients' quality of life. Despite advancements in treatment options, many patients continue to experience substantial disease burden and unmet needs.
Data Highlights
Finding
Percentage
Patients with active disease
57.1%
Impaired quality of life
76.4%
Work productivity loss
30.3%
Activity impairment
38.4%
Moderate-to-severe depressive symptoms
~50%
Dissatisfaction with advanced therapy
39.1%
Reduced adherence to therapy
10.9%
Key Findings
57.1% of patients reported active disease.
76.4% experienced impaired quality of life.
30.3% reported work productivity loss.
38.4% had activity impairment.
39.1% expressed dissatisfaction with their advanced therapy.
Clinical Implications
The findings indicate a need for enhanced management strategies for IBD patients to address ongoing symptoms and dissatisfaction with treatment. Clinicians should consider integrating patient-reported outcomes into routine assessments to better understand and address the multifaceted challenges faced by these patients.
Conclusion
Despite the availability of advanced therapies, the burden of IBD remains significant among patients in Greece.
